Melatonin in New Zealand: Reading the Label, the Evidence, and the Rules

A bottle of melatonin can look like a simple answer to a hard night: take a tablet, switch off, sleep. In New Zealand, that framing misses an important fact. Melatonin is regulated as a medicine, and the way it is supplied depends on the formulation, dose, pack and reason for use. It is not a general wellness supplement that belongs in an automatic bedtime routine.

Melatonin is a hormone made by the brain in response to darkness. It helps set the timing of the body clock. That makes it relevant to particular sleep and timing problems, but it does not make every sleepless night a melatonin problem. This guide explains what the label and the New Zealand rules mean, where the evidence is strongest, and the questions worth taking to a pharmacist or clinician.

Melatonin is a timing signal, not a sedative shortcut

The pineal gland releases melatonin in response to darkness. The hormone helps communicate that it is biological night and contributes to the timing of circadian rhythms, the roughly 24-hour processes that influence sleep and wakefulness. Exposure to light at night can suppress that signal. The National Center for Complementary and Integrative Health describes melatonin as a hormone the brain produces in response to darkness, with a role in circadian timing and sleep.

That description helps explain a common misunderstanding. Melatonin is not simply a stronger version of feeling tired. Medicines such as sedative-hypnotics are intended to induce or prolong sleep through different mechanisms. Melatonin is often described in clinical guidance as a chronobiotic because its principal role is to influence sleep timing. Taking it at the wrong time can work against the schedule someone is trying to keep.

bpacnz notes that a typical melatonin pattern begins about 14 hours after spontaneous waking, peaks around 2 to 3 am, and falls away by morning in a person with a usual sleep-wake cycle. Individual biology varies, and a night of poor sleep does not prove that a person is deficient in melatonin. Stress, pain, caffeine, alcohol, medicines, sleep apnoea, restless legs, depression, a noisy room and irregular hours can all be relevant to sleep without being solved by changing one hormone signal.

The practical point is modest but useful: start by identifying the problem. Is the difficulty falling asleep at the desired time, waking repeatedly, waking too early, recovering from travel across time zones, or feeling exhausted despite enough time in bed? Those patterns are not interchangeable, and neither is the evidence for melatonin.

It also helps to notice how melatonin differs from caffeine or a sedative in everyday thinking. Caffeine blocks a signal that promotes sleepiness; a sedative directly suppresses arousal pathways. Melatonin instead nudges the internal clock toward a particular phase. Given at the wrong clock time, it can shift sleep later instead of earlier, which is why generic “take one before bed” advice can misfire for a person whose problem is actually a delayed circadian rhythm rather than a lack of a sleep signal.

New Zealand treats melatonin as a medicine

A person who has seen melatonin gummies or large-dose tablets online may assume the same products are supplied in New Zealand as ordinary supplements. They are not. Medsafe states that approved melatonin-containing medicines can be supplied through pharmacies under particular conditions, while unapproved products remain subject to prescription requirements.

The regulatory details changed in 2025. Medsafe says the classification changed on 18 June 2025 to enable pharmacy supply of approved melatonin medicines without a consultation with a doctor or pharmacist. Companies may apply to approve products containing enough melatonin for consumers to use for up to 10 days for jet lag and up to 30 days for insomnia. This sits alongside the earlier route for a larger pharmacist-supplied pack for adults aged 55 years and over, for up to 13 weeks.

That does not mean every melatonin product sold overseas is automatically appropriate to import or use here. Medsafe specifically cautions that people importing an unapproved melatonin supply for personal use still need a prescription. It notes risks with unapproved medicines, including poor quality, variable potency, contamination and undisclosed ingredients.

“Melatonin is a restricted medicine in New Zealand. In some other countries, such as the United States, melatonin is considered a dietary supplement and can be purchased over the counter.” — bpacnz, Melatonin: is it worthwhile for sleep?

The distinction matters because internet shopping can make regulatory differences invisible. A polished overseas listing may use the word “supplement,” but that does not establish its New Zealand status, its quality, or whether its dose and formulation fit the reason a person wants it. A pharmacy conversation is not an obstacle to work around. It is a chance to check the product, the intended use, other medicines and the duration of use.

The format changes how the medicine behaves

Melatonin is sold in immediate-release and modified-release forms. Those names describe release behaviour, not a quality ranking. Immediate-release products produce a faster rise in melatonin level. Modified-release products release the medicine over longer periods and more closely resemble the shape of the body’s overnight melatonin pattern.

bpacnz reports that large head-to-head trials comparing the formats are lacking. There is limited evidence that the initial rise from either form can reduce sleep-onset latency in some contexts. Modified-release melatonin may also improve perceived sleep quality and morning alertness for some people. A result from one formulation cannot simply be copied across to another.

This is why the front of the pack is not enough. Read the active ingredient, the strength per dose unit, whether it says immediate or modified release, the directions, and the stated indication. A 2 mg modified-release tablet and a higher-strength immediate-release product do not make the same claim about how they will act through the night.

Medsafe’s 2019 classification described one established pharmacy pathway: oral immediate-release dose units of 3 mg or less, or modified-release units of 2 mg or less, in an approved manufacturer’s pack, for primary insomnia in adults aged 55 or older and for up to 13 weeks through a registered pharmacist. The current 2025 framework adds shorter approved pharmacy pathways for jet lag and insomnia. The safest way to apply a changing classification is not to memorise a number from an old article. Check with a New Zealand pharmacist whether the exact approved product and its directions apply to you.

The evidence is clearest for particular situations

Melatonin is often talked about as though it has one universal sleep effect. The research is more specific. NCCIH says melatonin supplements may help with jet lag, delayed sleep-wake phase disorder, some sleep disorders in children and anxiety before and after surgery. The evidence, benefits and risks differ across those uses.

For jet lag, NCCIH summarises reviews in travellers crossing multiple time zones. In four studies with 142 travellers, melatonin may have been better than placebo for reducing overall symptoms after eastward flights. The source also describes studies after westward flights. Those results do not show that melatonin improves every kind of fatigue or that it is necessary for every trip. They support a narrower proposition: timing may help some travellers manage a temporary circadian mismatch.

For delayed sleep-wake phase disorder, people tend to become sleepy much later than socially desired and have difficulty waking early. NCCIH reports that an American Academy of Sleep Medicine recommendation for specifically timed melatonin was weak, reflecting uncertainty about whether benefits outweigh harms. A 2018 randomised trial of 307 people combined melatonin one hour before the desired bedtime with a fixed bedtime schedule. Participants fell asleep an average of 34 minutes earlier and reported improvements in part of the night and daytime functioning. Timing and the accompanying routine were part of the intervention.

For chronic insomnia, the case is less sweeping than many labels imply. NCCIH states that 2016 American College of Physicians guidance strongly recommended cognitive behavioural therapy for insomnia, or CBT-I, as the initial treatment. It also says there was not enough strong evidence on melatonin’s effectiveness or safety in chronic insomnia to recommend supplementation in the cited guidelines. That does not mean nobody benefits. It means a persistent sleep problem deserves assessment and a plan rather than repeated self-directed trials.

New Zealand guidance reaches a similarly practical conclusion. bpacnz says behavioural interventions and good sleep hygiene remain first-line for most sleep disturbance. Medicines may be considered when those approaches are insufficient, but melatonin should not be prioritised over evidence-based care. It is a more useful standard than asking whether melatonin is “good” or “bad.”

A label cannot diagnose the reason you are awake

Many people first seek a sleep product after a few difficult weeks. The temptation is to treat the symptom as the diagnosis. That can delay attention to a cause that needs a different response.

A sleep diary can offer more useful information than a new bottle. For one or two weeks, record wake time, bedtime, estimated time to fall asleep, night wakings, naps, caffeine, alcohol, exercise, screens or bright light late at night, shift patterns and medicines. The aim is not perfection. It is to see whether there is a stable timing pattern or a clear trigger.

Consider a clinician review sooner rather than later if sleep difficulty is persistent, causes substantial daytime impairment, comes with loud snoring or breathing pauses, follows a major mood change, involves dangerous sleepiness when driving, or is paired with unexplained weight change, pain or neurological symptoms. Those are not problems to solve by escalating a dose from an overseas website.

For ordinary habits, the basics are unglamorous because they work on the conditions around sleep rather than on a single symptom. Keep a consistent wake time where possible. Get daylight early in the day. Protect a wind-down period. Keep caffeine timing in view. Make the bedroom suitable for sleep. For someone working nights or rotating shifts, the approach may need tailored advice because light exposure and sleep timing become more complicated.

These steps are not presented as a promise that everyone will sleep well immediately. They are the foundation that clinical guidance puts first. If a person eventually uses an approved melatonin medicine, the routine still matters. The medicine does not replace a sleep schedule.

With many nutrient supplements, a label question is simply how much. Melatonin adds another: when? Taking a product later because someone is still awake may sound logical, but it can create morning drowsiness or shift a circadian signal in an unhelpful direction.

bpacnz advises discussing consistent timing if melatonin is considered. Its guidance says modified-release melatonin is generally taken one to two hours before bedtime, and warns that incorrect timing can cause daytime sleepiness or other effects on circadian rhythms. A pharmacist or prescriber can give directions for the particular product and purpose; that is more reliable than copying an influencer’s routine.

The product instructions matter, too. Do not crush, split or chew a modified-release tablet unless the medicine information specifically says that is acceptable. Altering a release formulation can change the delivery the product was designed to provide. Similarly, do not combine multiple sleep products casually. “Natural,” “night-time,” “calm” and “sleep support” are marketing categories, not a guarantee that ingredients do not overlap or affect alertness.

There is no established dietary recommended daily allowance for melatonin in the way there is for vitamin C or zinc. It is a hormone used as a medicine in New Zealand, not a nutrient target to chase. That is another reason that a large number on an online product is not evidence of a better outcome.

Clinical trials in the areas NCCIH summarises have generally used low, targeted doses rather than the largest number available on a shelf. That pattern is worth remembering before assuming a higher milligram figure automatically means a stronger or faster effect; melatonin does not appear to work on a simple more-is-better curve the way a painkiller might.

Children need a different level of caution

Adult-focused social media advice is especially unsuitable for children. Children’s sleep changes with age, development, school schedules, neurodevelopmental conditions and family routines. A child who struggles to sleep may need an assessment of the pattern and its cause, not a borrowed gummy.

NCCIH says there are uncertainties about dose, timing, long-term effects and the balance of benefit and risk for children using melatonin. The organisation notes that research on children is often short, and that there are unresolved questions about possible effects on hormonal development. It recommends working with a health care provider when considering melatonin for a child’s sleep problems.

New Zealand rules also make the point concrete. bpacnz reports that modified-release melatonin can be funded with Special Authority for persistent, distressing insomnia secondary to a neurodevelopmental disorder in people aged 18 or under, after behavioural and environmental approaches have been tried, failed or are inappropriate. Initial approval is specialist-led. That is very different from treating a child’s bedtime resistance with an adult’s leftover medicine.

Safe storage matters regardless of the intended user. In a United States CDC analysis of poison-centre data from 2012 to 2021, 260,435 paediatric melatonin ingestions were reported. The annual number increased 530% over the period. Most were unintentional, most involved children aged five or younger, and most were managed outside a health-care setting. But the report also recorded hospitalisations, intensive-care admissions, five children who required mechanical ventilation and two deaths in children younger than two. Those figures are US data from a market where melatonin is widely available as a supplement, not estimates for New Zealand. They still provide a clear household lesson: keep medicines and supplements out of children’s reach and sight, especially sweet or gummy formats.

If a child may have taken melatonin or another medicine unintentionally, seek urgent poison or medical advice rather than waiting to see what happens. In New Zealand, the National Poisons Centre can be reached on 0800 POISON (0800 764 766).

Quality and online claims deserve scepticism

A clean-looking label is not a laboratory result. Quality concerns are one reason overseas direct-to-consumer products deserve more scrutiny than their packaging invites.

NCCIH describes a 2023 study of 25 over-the-counter melatonin gummy products. Twenty-two were inaccurately labelled. One had no detectable melatonin, and measured levels in the remaining products ranged from 74% to 347% of the labelled quantity. The same NCCIH guidance cites a 2017 study of 31 melatonin supplements in which most products did not match their labels and 26% contained serotonin.

Those studies examined products in the United States. They do not prove that every product in another country is inaccurate, and they do not assess a specific approved New Zealand medicine. Their relevance is narrower: a dose printed on an unregulated or unfamiliar product should not be assumed to be a precise promise. That is particularly important when a product looks like confectionery or is marketed for children.

Medsafe’s warning on personal imports points to the same practical concern. Unapproved products can have variable potency, contamination or undisclosed ingredients. Buying from a pharmacy does not eliminate every medical question, but it gives the purchaser a regulated supply route and an opportunity for individual advice.

Be cautious with claims that a melatonin product will “reset hormones,” repair every night of poor sleep, treat anxiety, prevent disease, or replace medical care. NCCIH says research on melatonin for COVID-19 remains too early for conclusions, and that studies on cancer symptoms or treatment side effects have been small and mixed. Melatonin should never replace or delay conventional cancer care.

Medicines, pregnancy and daytime safety

“Short-term” is not the same as “risk-free.” NCCIH says short-term melatonin use appears safe for most people, but long-term safety information is lacking. It identifies particular areas for discussion with a clinician or pharmacist.

People who take any regular medicine should mention it before starting melatonin. NCCIH specifically says people with epilepsy and those taking blood-thinning medicines need medical supervision when using melatonin. It also notes limited safety research in pregnancy and breastfeeding. Older adults may experience melatonin activity for longer and may have daytime drowsiness; the cited American Academy of Sleep Medicine guidance recommends against its use in people with dementia.

Daytime drowsiness changes practical safety. Do not drive, cycle in traffic, use machinery or make high-consequence decisions if a medicine leaves you less alert than usual. Alcohol can further complicate sleep quality and next-day impairment, so it is not a sensible add-on to a sleep medicine routine.

A good pharmacy conversation should include:

• The exact sleep or timing problem you want to address.
• Your age, pregnancy or breastfeeding status, and relevant medical conditions.
• Every prescription medicine, over-the-counter product and supplement you take.
• Whether you need to drive, care for children overnight, work shifts or operate machinery.
• The product’s formulation, directions and intended short duration.

That list is not bureaucracy. It is how a generic bedtime product becomes a safer, individual decision.

How to read a melatonin product without over-reading it

A label can tell you what a product contains and how its maker instructs it to be used. It cannot tell you whether it is the right response to your sleep problem. Use the label as a starting point, not a diagnosis.

First, confirm it is an approved New Zealand product supplied through an appropriate route. Next, identify the formulation: immediate-release or modified-release. Then read the strength, dose instructions, warning statements and treatment duration. If the product is supplied for jet lag, do not assume its directions transfer to ongoing insomnia. If it is intended for a short course, do not quietly turn it into a permanent nightly habit.

Avoid product stacking. A person may take an evening herbal blend, an antihistamine-containing “night” product, alcohol, a magnesium powder and melatonin without realising how much of the routine has changed. Bring the actual containers or clear photos of labels to a pharmacist instead of relying on memory.

Also notice what the label does not say. It will not identify sleep apnoea. It will not distinguish grief, pain, a medication side effect, depression, a circadian delay or an unsuitable work roster. The absence of a warning on a retail page is not evidence that there is no risk for you.

Treat the label the way you would treat any medicine information leaflet: as a set of facts to verify with a professional, not as a persuasive pitch to accept at face value. If a listing is heavy on lifestyle imagery and light on active ingredient, strength, formulation and directions, that absence is itself informative.

The useful next step is a defined, reviewable plan

Melatonin has a legitimate place in sleep medicine. The evidence supports defined uses more than it supports the idea of a universal sleep supplement. In New Zealand, the regulatory setting reinforces that distinction: it is a medicine with approved supply pathways, not a casual replacement for sleep assessment.

If sleep is occasionally disrupted by travel, ask a pharmacist about the appropriate approved option and timing. If the issue is ongoing, start with the pattern, the routine and the possible causes. A persistent problem deserves more than a larger dose and a hopeful review posted at 2 am.

The best label-reading habit is to ask one question before buying: what exactly is this product meant to help with, and does that match my situation? A clear answer is more valuable than a dramatic milligram number.

Sources: Medsafe, “Melatonin without a prescription” (revised 20 October 2025); bpacnz, “Melatonin: is it worthwhile for sleep?” (19 January 2024); NCCIH, “Melatonin: What You Need To Know”; CDC MMWR, “Pediatric Melatonin Ingestions, United States, 2012–2021”; JAMA, “Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US” (2023).

Sources

www.medsafe.govt.nz

bpac.org.nz

www.nccih.nih.gov

www.cdc.gov

jamanetwork.com

www.medsafe.govt.nz

This article is for general education and does not replace advice from a qualified healthcare professional.